IHS Chemical Week

EnviroTech :: Manufacturing Excellence

Lonza Signs Manufacturing Deal with U.S. Biopharma Firm

12:30 AM MDT | May 19, 2009 | Deepti Ramesh

Lonza says it has entered into a manufacturing services agreement with biopharmaceutical company Morphotek (Exton, PA), to support the development and manufacturing of a subset of antibodies in Morphotek’s therapeutic antibody pipeline. According to the agreement, Lonza will reserve capacity for commercial manufacturing of Morphotek’s lead compound farletuzumab, which recently entered Phase III clinical trials for ovarian cancer. Morphotek, a subsidiary of pharmaceutical company Eisai Corporation (Woodcliff Lake, NJ), specializes in the development of...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa